NeOnc Sets 610 mg RP2D for NEO212, Enrolls NEO100 Trial and Secures $10 M
NeOnc completed Phase 1 dose escalation for NEO212, establishing a 610 mg Phase 2 dose with anti-tumor activity signals in recurrent GBM and brain metastasis patients. The company fully enrolled the NEO100 Phase 2a IDH1-mutant glioma trial, with 24% radiographic remission, 44% six-month progression-free survival and a $10 million PIPE financing.
1. Clinical Milestones
NeOnc completed Phase 1 dose escalation for NEO212, setting a 610 mg recommended Phase 2 dose with early anti-tumor efficacy signals in heavily pretreated glioblastoma and brain metastasis patients. The NEO100 Phase 2a IDH1-mutant high-grade glioma study is fully enrolled and updated Phase 1/2a data showed a 24% radiographic remission rate and 44% six-month progression-free survival.
2. Financing and Corporate Updates
The company secured $10 million in a PIPE financing anchored by Cinctive Capital, strengthening the balance sheet to advance clinical priorities. Leadership was bolstered with the appointments of Amir Heshmatpour as CEO, David Choi as CAO and two leading neuro-oncologists added to the scientific advisory board.
3. Upcoming Catalysts
NeOnc plans to request a Type B End-of-Phase 1 FDA meeting for NEO212 to align on a pivotal Phase 2 study and expects preliminary NEO100 Phase 2a data readout in approximately five months, presenting key value-creating milestones.